ICPA launches Mucofibro softgel capsules to aid in healing of oral lesions & precancerous conditions

ICPA Health Products Ltd (ICPA), a leading pharma company in the oral healthcare segment, has launched its latest oral healthcare product– Mucofibro. Available in the form of soft-gel capsules, the product is targeted towards promoting the healing of a variety of oral lesions and improving the treatment outcomes of both, non-surgical and surgical dental procedures.
 
Mucofibro helps prevent the malignant transformation of precancerous lesions like oral leukoplakia and erythroplakia and also improves the treatment outcomes in precancerous conditions like oral submucous fibrosis (OSMF). The product is a recommended supplementation for improved clinical results in a variety of oral, periodontal and implant surgical procedures.
 
Packed with powerful antioxidants, carotenoids and minerals, Mucofibro prevents cell damage by fighting the oxidative stress inside the cells and restores the tissue healing capacity. With its powerful ‘cell detoxification action’ Mucofibro is beneficial in improving the clinical outcomes in non-cancer, pre-cancer and cancer treatments.
 
“India is considered the world capital for oral cancer contribution with one-third of the global burden. Mucofibro will play a big role in preventing the malignant transformation of precancerous lesions like oral leukoplakia and erythroplakia, and improving the treatment outcomes in precancerous conditions like oral submucous fibrosis where the common symptoms are burning mouth and reduced mouth opening. With its expanding scope in periodontics and implantology because of the new scientific evidence, Mucofibro aims to improve the clinical results in periodontology and the rapidly growing dental implantology segment,” says Abha Damani, Director, ICPA.
 
The nutritional supplement product category is valued at Rs.101 crore and has witnessed a positive growth in both its revenue at 14 per cent and the unit growth at 2 per cent. Each soft gelatin capsule contains lycopene - 5 mg, beta-carotene - 10 mg, alpha lipoic acid 50 mg, elemental copper - 1 mg, elemental selenium - 75 mcg, vitamin E - 10IU and zinc sulphate - 27.45 mg.
 
“With the introduction of Mucofibro, ICPA aims to capture a lion’s share of dental practice including general dental practitioners & specialists in oral medicine radiology, oral & maxillofacial surgery, periodontics and implantology, general medical practitioners, ENT, and oncology specialists,” concluded Damani.
 
The product will be available across all leading pharmacies in the country as well as through popular e-pharmacies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!